IMMUNOHISTOCHEMICAL EXPRESSION OF CD133 STEM CELL MARKER IN PRIMARY OSTEOSARCOMA

Abstract

The current study included 44 osteosarcoma cases collected in duration of 2010 to 2014; 35 osteosarcoma cases with history of preoperative chemotherapy and 9 osteosarcoma cases without history of preoperative chemotherapy as control. The specimens were obtained from the Pathology Department, Al-Demerdash Hospital, Ain Shams University Specialized Hospital and Nasser Institute for research & treatment. All cases were studied along the following lines: (I) Demographic and clinical studies: by reviewing the files of the patients for age, sex, tumor site, size and recurrence. (II) Histopathologic study: by reexamining the Hx&E slides for: - Confirmation of the diagnosis of osteosarcoma and determination of the type of the tumor. - Osteosarcoma cases were graded into low and high grade according to WHO classification. All cases were staged according to TNM staging system and AJCC staging system. (III) Immunohistochemical study: - Immunohistochemical examination of OS cases for CD133 stem cell marker. (IV) Finally, correlation of the expression of CD133 stem cell marker with the different clinicopathological parameters of OS as regards; age, sex, tumor site, tumor size, tumor histopathologic type, tumor grade, TNM stage, tumor necrosis index and infiltration of the surrounding soft tissue. Our study revealed high expression of CD133 in 51.4% of group1 and 44.4% of group 2 and low CD133 expression in 48.6% of group 1and 55.6% of group 2. Concerning the correlation between CD133 expression and clinicopathological features of OS cases, the present study revealed a statistical significant inverse relation between mean of CD133expression for patients who received preoperative chemotherapy and TNI (P= 0.003).